宫颈球囊导管与Dilapan-S用于门诊宫颈成熟的随机对照试验
这项单盲随机对照试验在单家三级医院纳入80例符合条件的足月单胎头位、无剖宫产史孕妇,比较Dilapan-S与宫颈球囊导管用于门诊宫颈成熟的效果。主要结局Bishop评分变化两组无差异(中位变化3.0 vs 3.0,P=.91),Dilapan-S组满意度更高且宫颈成熟失败复合结局更少。结论为基于Bishop评分变化Dilapan-S不劣于宫颈球囊导管。
要点
- 在80例门诊宫颈成熟孕妇中,Dilapan-S与宫颈球囊导管的Bishop评分中位变化均为3.0。
- Dilapan-S组满意度中位评分为9,宫颈球囊导管组为8(P<.01)。
- Dilapan-S组宫颈成熟失败复合结局发生率为17.5%,低于球囊导管组的45.0%(P<.01)。
核心结论
- 基于Bishop评分变化,Dilapan-S用于门诊宫颈成熟不劣于宫颈球囊导管。
- 与单球囊充气的宫颈球囊导管相比,参与者对Dilapan-S更满意,且宫颈成熟失败可能性更低。
研究设计与样本
- 单盲随机对照试验,在单家三级医院开展,时间为2022年5月至2023年6月。
- 纳入18至50岁、足月、单胎头位、无剖宫产史、按既有医院政策安排门诊宫颈成熟的初产与经产孕妇,共随机80例。
- 参与者随机接受宫内球囊充注60 mL的Cook导管单球囊宫颈成熟或放置3至5根Dilapan-S亲水性扩张器后离院。
- 主要结局为Bishop评分变化;检验不劣性的把握度为80%,非劣效界值为2,标准差为3。
主要发现
- 两组基线人口学数据、初始扩张程度及Bishop评分无差异,每组70%的参与者为初产妇。
- Dilapan-S组与宫颈球囊导管组的Bishop评分中位变化分别为3.0(四分位距2.0-5.0)与3.0(四分位距2.0-4.5),P=.91。
- 分娩时间、分娩方式及母儿结局均无差异。
- Dilapan-S组满意度中位评分为9(四分位距8-10),宫颈球囊导管组为8(四分位距5-9),P<.01。
- Dilapan-S组宫颈成熟失败复合结局为7例(17.5%),宫颈球囊导管组为18例(45.0%),P<.01。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: As labor induction increases in the United States, safe and effective outpatient cervical ripening has been explored as a method to decrease the inpatient time burden. However, the most effective method for outpatient mechanical cervical ripening remains unclear. OBJECTIVE: This study aimed to evaluate whether Dilapan-S is noninferior to a cervical balloon for outpatient cervical ripening based on the change in Bishop score. STUDY DESIGN: This single-blind randomized controlled trial was conducted at a single tertiary hospital. Term patients, both nulliparous and multiparous, aged 18 to 50 years with a singleton cephalic fetus and no previous cesarean delivery who were scheduled for outpatient cervical ripening per preexisting hospital policy were eligible. Participants were randomized to single-balloon cervical ripening with a Cook catheter with 60 mL in the intrauterine balloon or placement of 3 to 5 Dilapan-S hydroscopic dilators and were discharged. Upon returning to the hospital, the cervical ripening agent was removed, a blinded cervical examination was performed, and the participants completed a satisfaction survey. Further labor induction was performed as per the obstetrical provider. The primary outcome was change in Bishop score. The secondary outcomes included patient satisfaction, mode of delivery, labor induction time, adverse maternal and neonatal outcomes, and cervical ripening failure composite (failure to place a randomized cervical ripening agent, premature rupture of membranes before a scheduled return to the hospital, significant vaginal bleeding, or need for further cervical ripening after the initial agent is removed). This study had 80% power to show noninferiority in change in Bishop score, with a margin of 2 and a standard deviation of 3. RESULTS: From May 2022 to June 2023, 80 participants were randomized, with no difference in baseline demographic data, starting dilation, or Bishop score. Of note, 70% of the participants in each arm were nulliparous. There was no difference in change in Bishop score between Dilapan-S and the cervical balloon catheter (median change: 3.0 [interquartile range, 2.0-5.0] vs 3.0 [interquartile range, 2.0-4.5], respectively; P=.91). There was no difference in the time to delivery, mode of delivery, or maternal or neonatal outcomes. Compared with participants randomized to a cervical balloon catheter, those randomized to Dilapan-S were more satisfied with their experience than (satisfaction scale of 0-10; median: 8 [interquartile range, 5-9] vs 9 [interquartile range, 8-10], respectively; P<.01) and were less likely to experience cervical ripening failure (18 (45.0%) vs 7 (17.5%), respectively; P<.01). CONCLUSION: Dilapan-S was noninferior to a cervical balloon catheter for outpatient cervical ripening based on the change in Bishop score. The participants were more satisfied with Dilapan-S and less likely to experience cervical ripening failure than with a cervical balloon catheter with single-balloon inflation. El resumen está disponible en Español al final del artículo.
引用
- Wood RL, Bluemm C, Lassey SC, et al. Cervical balloon catheter vs Dilapan-S for outpatient cervical ripening: a randomized controlled trial. Am J Obstet Gynecol MFM. 2025. PMID: 39818274. doi:10.1016/j.ajogmf.2025.101608
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。